Trials / Completed
CompletedNCT00992563
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
A Dose-Escalation Study of AL-39324 Suspension Versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
Detailed description
Following a single administration, patients will be followed for 6 months postinjection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL-39324 ophthalmic suspension | |
| DRUG | Ranibizumab 10 mg/mL |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2009-10-09
- Last updated
- 2014-07-18
Source: ClinicalTrials.gov record NCT00992563. Inclusion in this directory is not an endorsement.